Rejection is always painful, but it is particularly agonising to have a drug rejected at the point of regulatory approval. After spending months researching, preparing, manufacturing and quality checking a drug, only to be sent back to the drawing board, how can companies get back into their creationary swing straight away?

The corporate environment is evolving, and ‘purpose’ is more important than ever to young recruits looking for their next role. We examine how the pharmaceutical industry is embracing the importance of purpose for retention, reputation, and brand differentiation

From drug development to disposal, how can all processes and functions be considered through a greener lens, and work towards a healthier and safer future?

While the potential of cell and gene therapies (CGTs) is huge, the high cost raises concerns from payers. We explore how the industry can drive the adoption of CGTs to ensure that they reach patients around the world, rather than just those in private markets

During the pandemic, low-to-middle-income countries (LMICs) have often been reliant on vaccine handouts from global initiatives and affluent nations. What are the emerging solutions that could improve access to vaccines in LMICs and self-sufficiency?

Tech giants have seized a huge share of the health and preventive technology market, but how could partnerships between the pharmaceutical and tech industries benefit patients and healthcare systems?

To do well at digital transformation, pharma leaders must balance skills development with maintaining employee morale.

Christine Miller is the President, Chief Executive Officer, and member of the board, Melinta Therapeutics, speaks to us about her path into the pharmaceutical industry, her mission to end antimicrobial resistance, and how to be an effective leader in pharma today